Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Renal Cell
  • Imidazoles
  • Indazoles
  • Kidney Neoplasms
  • Protein Kinase Inhibitors

abstract

  • Axitinib was well tolerated and provided an estimated 5-year survival rate of 20.6% for cytokine-refractory metastatic renal cell carcinoma. Exploratory analyses showed numerically higher objective response rate and longer OS and PFS in patients who achieved post-first-dose axitinib plasma concentrations within a specific range.

publication date

  • June 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.clgc.2012.12.004

PubMed ID

  • 23391371

Additional Document Info

start page

  • 107

end page

  • 14

volume

  • 11

number

  • 2